BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...

AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands ? Royal Philips , a global ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...